Keratocan Inhibitors
The class of Keratocan inhibitors represents a diverse repertoire of chemical compounds meticulously engineered to intricately modulate cellular processes and signaling pathways, thereby effecting the potent inhibition or modulation of Keratocan. These inhibitors operate with precision, targeting specific biochemical and cellular pathways to disrupt the elaborate network that governs the expression and functionality of Keratocan within cells. A noteworthy exemplar within this class is BAPTA-AM, which exerts its inhibitory action by chelating intracellular calcium ions. This mechanism disrupts calcium-dependent signaling pathways intricately associated with Keratocan modulation, offering a targeted approach to impede its expression and function. Similarly, SB-431542 emerges as a distinct Keratocan inhibitor by selectively targeting the TGF-β receptor. This targeted intervention effectively impedes TGF-β signaling, a pivotal pathway crucial for the regulation of Keratocan. In a parallel vein, Y-27632 inhibits Keratocan by targeting Rho-associated protein kinase (ROCK), disrupting the Rho/ROCK signaling pathway intricately implicated in the modulation of Keratocan.
Collectively, these inhibitors epitomize the finesse achieved in targeting Keratocan, demonstrating a high degree of precision and specificity in their interactions with key signaling pathways and cellular processes. The detailed elucidation of their mechanisms of action provides researchers with the foundational knowledge required to craft interventions precisely aimed at attenuating Keratocan activity within various cellular contexts. This understanding not only paves the way for targeted strategies but also serves as a springboard for further exploration into the intricate regulatory networks that underlie the biology of Keratocan, fostering a deeper comprehension of its roles in physiological and pathological processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM inhibits Keratocan by chelating intracellular calcium ions. As a cell-permeable acetoxymethyl ester of BAPTA, it effectively sequesters calcium ions within the cytoplasm, disrupting calcium-dependent signaling pathways that play a crucial role in Keratocan modulation. This chelation interferes with downstream cellular processes, leading to the inhibition of Keratocan and its associated functions in extracellular matrix maintenance. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 inhibits Keratocan by selectively targeting the TGF-β receptor. As an Alk5 inhibitor, it hampers TGF-β signaling, a pathway intricately involved in Keratocan regulation. By specifically impeding Alk5 kinase activity, SB-431542 disrupts the downstream events that culminate in Keratocan expression and modulation. This targeted inhibition offers a precise means to attenuate Keratocan function within cellular contexts influenced by TGF-β signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits Keratocan by targeting Rho-associated protein kinase (ROCK). As a selective ROCK inhibitor, Y-27632 interferes with the Rho/ROCK signaling pathway, which is implicated in Keratocan modulation. By blocking ROCK activity, Y-27632 disrupts the downstream events that contribute to Keratocan expression and function, providing a specific means to attenuate Keratocan activity in cellular processes influenced by Rho/ROCK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits Keratocan by targeting MEK1/2 in the MAPK pathway. As a selective MEK inhibitor, PD98059 disrupts the MAPK signaling cascade, which is intricately involved in Keratocan modulation. By specifically blocking MEK1/2 activity, PD98059 interferes with the downstream events that lead to Keratocan expression and function, providing a targeted approach to attenuate Keratocan activity in cellular contexts influenced by MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits Keratocan by targeting JNK in the MAPK pathway. As a selective JNK inhibitor, SP600125 disrupts the MAPK signaling cascade, which plays a role in Keratocan modulation. By specifically blocking JNK activity, SP600125 interferes with the downstream events that lead to Keratocan expression and function, providing a specific means to attenuate Keratocan activity in cellular contexts influenced by the JNK arm of the MAPK pathway. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A83-01 inhibits Keratocan by selectively targeting the TGF-β receptor. As an Alk5 inhibitor, it disrupts TGF-β signaling, a pathway intricately involved in Keratocan regulation. By specifically impeding Alk5 kinase activity, A83-01 interferes with the downstream events that lead to Keratocan expression and modulation, offering a precise means to attenuate Keratocan function within cellular contexts influenced by TGF-β signaling. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $336.00 $1642.00 | 20 | |
Calphostin C inhibits Keratocan by targeting PKC. As a potent PKC inhibitor, Calphostin C disrupts the PKC signaling pathway, which is implicated in Keratocan modulation. By specifically blocking PKC activity, Calphostin C interferes with the downstream events that contribute to Keratocan expression and function, providing a targeted approach to attenuate Keratocan activity in cellular contexts influenced by PKC signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits Keratocan by targeting PI3K in the PI3K/AKT signaling pathway. As a potent PI3K inhibitor, LY294002 disrupts the PI3K/AKT pathway, which is intricately involved in Keratocan modulation. By specifically blocking PI3K activity, LY294002 interferes with the downstream events that lead to Keratocan expression and function, providing a specific means to attenuate Keratocan activity in cellular contexts influenced by the PI3K/AKT signaling pathway. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 (AG-490) inhibits Keratocan by targeting JAK2 in the JAK/STAT signaling pathway. As a selective JAK2 inhibitor, AG-490 disrupts the JAK/STAT pathway, which plays a role in Keratocan modulation. By specifically blocking JAK2 activity, AG-490 interferes with the downstream events that lead to Keratocan expression and function, providing a specific means to attenuate Keratocan activity in cellular contexts influenced by the JAK/STAT signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB-203580 inhibits Keratocan by targeting p38 in the MAPK pathway. As a selective p38 inhibitor, SB-203580 disrupts the MAPK signaling cascade, which is intricately involved in Keratocan modulation. By specifically blocking p38 activity, SB-203580 interferes with the downstream events that lead to Keratocan expression and function, providing a targeted approach to attenuate Keratocan activity in cellular contexts influenced by p38-mediated signaling. | ||||||